Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies

Table 2 List of drugs used in this study

Target	Drug name	Company	Cat. No	Max screening conc. (µM)
BRAF^V600E	Vemurafenib	TargetMol	T2382	10
BRAF^V600E	Dabrafenib	MedChemExpress	HY-14660	10
MEK1	Selumetinib	MedChemExpress	HY-50706	10
MEK1/2	Trametinib	MedChemExpress	HY-10999	10
VEGFR, Raf-1	Sorafenib	MedChemExpress	HY-10201	10
VEGFR, PDGFRβ	Lenvatinib	MedChemExpress	HY-10981	10
VEGFR, c-Met	Cabozantinib	MedChemExpress	HY-13016	10
VEGFR, EGFR	Vandetanib	MedChemExpress	HY-10260	10
VEGFR, PDGFRβ	Sunitinib	MedChemExpress	HY-10255A	10
DNA topoisomerase II	Doxorubicin	MedChemExpress	HY-15142A	10
Microtubule	Vincristine	MedChemExpress	HY-N0488A	10
Microtubule	Paclitaxel	TargetMol	T0968	10
DNA synthesis	Cisplatin	TargetMol	T1564	10

ISSN: 1479-5876